

QUALIFIED CLINICAL DATA REGISTRY (QCDR) 2018 MEASURE SUMMARY

MEASURE#	MEASURE	NQF Endorsed Measure
QOPI 5	Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented (Lower Score - Better)	
QOPI 11	Combination chemotherapy received within 4 months of diagnosis by women under 70 with AJCC stage IA (T1c) to III ER/PR negative breast cancer	NQF Endorsed #0559
QOPI 15	GCSF administered to patients who received chemotherapy for metastatic cancer (Lower Score - Better)	NQF Endorsed #0326
QOPI 21	Oncology: Treatment Summary Communication – Radiation Oncology	NQF Endorsed #0381
QOPI 22	External Beam Radiotherapy for Bone Metastases	NQF Endorsed #1822
QPP 47	Care Plan	NQF Endorsed #0326
QPP 67	Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	NQF Endorsed #0377
QPP 69	Hematology: Multiple Myeloma: Treatment with Bisphosphonates	NQF Endorsed #0380
QPP 70	Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	NQF Endorsed #0379
QPP 102	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patient	NQF Endorsed #0389
QPP 104	Prostate Cancer: Adjuvant Hormonal Therapy for High Risk or Very High Risk Prostate Cancer	NQF Endorsed #0390
QPP 130	Documentation of Current Medications in the Medical Record	NQF Endorsed #00419
QPP 134	Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan	NQF Endorsed #00418
QPP 143	Oncology: Medical and Radiation - Pain Intensity Quantified	NQF Endorsed #0384
QPP 226	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	NQF Endorsed #0028
QPP 317	Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented	
QPP 408	Opioid Therapy Follow-up Evaluation	
QPP 449	HER2 Negative or Undocumented Breast Cancer Patients Spared Treatment with HER2-Targeted Therapies	NQF Endorsed #1857

QUALIFIED CLINICAL DATA REGISTRY (QCDR) 2018 MEASURE SUMMARY

MEASURE#	MEASURE	NQF Endorsed Measure
QPP 450	Trastuzumab Received By Patients With AJCC Stage I (T1c) - III And HER2 Positive Breast Cancer Receiving Adjuvant Chemotherapy	NQF Endorsed #1858
QPP 451	KRAS Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy	NQF Endorsed #1859
QPP 452	Patients with Metastatic Colorectal Cancer and KRAS Gene Mutation Spared Treatment with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies	NQF Endorsed #1860
QPP 453	Proportion Receiving Chemotherapy in the Last 14 Days of Life (Lower score - Better)	NQF Endorsed #0210
QPP 456	Proportion Not Admitted To Hospice	NQF Endorsed #0215
QPP 457	Proportion Admitted to Hospice for less than 3 days (Lower score - Better)	NQF Endorsed #0216
QPP 462	Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Therapy	